Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 18, 2013 (13 years ago)

Papaverine/Phentolamine 30 mg/mL/2.0 mg/mL Inj

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Papaverine/Phentolamine 30 mg/mL/2.0 mg/mL Inj, 5 mL units Rx Only, The Compounding Center at Blue Ridge, 2601 Blue Ridge Rd, Raleigh, NC 27607.

Drug: Papaverine

Recalling firm
Compounding Centre At Blue Ridge
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-405-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Papaverine recalls

See all
Class I · High risk

Papaverine HCl Injection

Presence of Particulate Matter: Product contaminated with particulate matter identified as glass and/or paraformaldehyde

Ongoing Particulate / foreign matter American Regent, Inc. NDC 0517-4002-01 D-0800-2026

Other recalls by Compounding Centre At Blue Ridge

All 2013 recalls
Class II · Moderate risk

Quad Mix Injectable

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Terminated Sterility / contamination Compounding Centre At Blue Ridge D-404-2014
Class II · Moderate risk

Super Triple Mix Injectable

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Terminated Sterility / contamination Compounding Centre At Blue Ridge D-403-2014
Class II · Moderate risk

PGE 20 mcg/mL Injectable

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Terminated Sterility / contamination Compounding Centre At Blue Ridge D-402-2014
Class II · Moderate risk

Triple Mix Injectable

Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.

Terminated Sterility / contamination Compounding Centre At Blue Ridge D-401-2014